反応式
[Cl:1][C:2]1[CH:21]=[CH:20][C:5]2[O:6][C:7]3[CH:19]=[CH:18][CH:17]=[CH:16][C:8]=3[C@@H:9]3[C@H:14]([NH2:15])[CH2:13][CH2:12][CH2:11][N:10]3[C:4]=2[CH:3]=1.[F:22][CH2:23][C:24](OCC)=[O:25]>>[Cl:1][C:2]1[CH:21]=[CH:20][C:5]2[O:6][C:7]3[CH:19]=[CH:18][CH:17]=[CH:16][C:8]=3[C@@H:9]3[C@H:14]([NH:15][C:24](=[O:25])[CH2:23][F:22])[CH2:13][CH2:12][CH2:11][N:10]3[C:4]=2[CH:3]=1参加物
3
実験手順
trans-7-Chloro-2,3,4,14b-tetrahydro-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-amine (10 mg, 0.03 mmol) was dissolved in 1 mL of ethyl fluoroacetate. The resulting mixture was heated to reflux for 2 h. Evaporation followed by crystallisation from methanol gave trans-N-(7-chloro-2,3,4,14b-tetrahydro-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-2-fluoroacetamide (4.7 mg, 39%). Data: (m/z)=361 (M+H)+.
後処理
- temperatureThe resulting mixture was heated
- temperatureto reflux for 2 h
- customEvaporation
- customfollowed by crystallisation from methanol
出典と根拠
- ORDレコード
- ord-9b14aaf8d506412094cc509974542c31
- 出典データセット
- uspto-grants-2010_06
- 特許番号
- US07737136B2
関連ノート
読み込み中…